Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.

导出 OA

翻译打印收藏纠错

作者： Chunsheng,Li ^[1] ; Junying,Wang ^[2] ; Jia,Hu ^[3] ; Yi,Feng ^[4] ; Kosei,Hasegawa ^[5] ; Xiaohui,Peng ^[3] ; Xingmei,Duan ^[3] ; Aizhi,Zhao ^[3] ; John L,Mikitsh ^[6] ; Vladimir R,Muzykantov ^[7] ; Ann-Marie,Chacko ^[8] ; Daniel A,Pryma ^[6] ; Steven M,Dunn ^[9] ; George,Coukos ^[10]

作者单位： Ovarian Cancer Research Center, University of Pennsylvania; These authors contributed equally to this work. ^[1] Ovarian Cancer Research Center, University of Pennsylvania; Department of Immunology, Norman Bethune College of Medicine Jilin University; These authors contributed equally to this work. ^[2] Ovarian Cancer Research Center, University of Pennsylvania. ^[3] Department of Cancer Biology, University of Pennsylvania. ^[4] Saitama International Medical Center Saitama Medical University. ^[5] Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania. ^[6] Institute for Translational Medicine and Therapeutics, University of Pennsylvania. ^[7] Institute for Translational Medicine and Therapeutics, University of Pennsylvania; Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, University of Pennsylvania. ^[8] Ludwig Cancer Research Center, University of Lausanne. ^[9] Ovarian Cancer Research Center, University of Pennsylvania; Ludwig Cancer Research Center, University of Lausanne. ^[10]